Cellevat3d® nanofiber microcarriers and macrocarriers
Cellevat3d® nanofiber microcarriers
Designed for highest yield and productivity in upstream bioprocessing of gene therapy applications.
Commercial launch November 2024.
We are on the brink of a biomanufacturing revolution
The emergence of therapeutical biologics like cell- and gene therapy marks the beginning of a new medical era, revolutionizing treatment across several fields and offering options for previously untreatable diseases. While the field has grown rapidly and is expected to continue expanding, challenges in manufacturing, such as low productivity, poor yields, and scaling issues, drive up costs and limits patient access. It has been noted that these high development cost could stall the market unless a second “Biomanufacturing Revolution” follows, highlighting the urgent need for new disruptive, scalable, and sustainable technologies to make these therapies more affordable.1
1) World Economic Forum. Accelerating the Biomanufacturing Revolution. Whitepaper. Feb 2022
Driven by microcarriers and macrocarriers
As the search for more affordable therapies intensifies, so does the quest for novel bioreactor microcarriers, and macrocarriers – advanced 3D structures capable of housing and supporting high-density, high-viability cell cultures more effectively than traditional scaffolds. These advancements aim to improve cell viability, yield and overall productivity. The microcarrier market is one of the fastest growing in the industry, projected to rise from EUR 2 billion in 2022 to an estimated EUR 4 billion by 2026. With the introduction of macrocarriers, this growth is expected to accelerate even further.
Introducing Cellevat3d® upstream product portfolios
Cellevate is responding to exactly these needs by offering innovative microcarrier and macrocarrier solutions for cell culture upstream bioprocessing that are scalable from lab- to production-scale.
The Cellevat3d® platform features two distinct product portfolios for industrial cell culture – Cellevat3d® nanofiber microcarriers and Cellevat3d® nanofiber macrocarriers – each tailored to specific needs, both engineered to revolutionize upstream bioprocessing and increase patient access to life-changing therapies such as cell and gene therapy and novel vaccines.
Cellevat3d®
– 1 platform, 2 upstream product lines
Our first upstream product line – Cellevat3d® nanofiber microcarriers – is designed for stirred tank bioreactor applications such as gene therapy, pluripotent stem cells (PSCs), organoid formation as well as HEK-based recombinant proteins and vaccines.
The second product line in development – Cellevat3d® nanofiber macrocarriers – is aimed for packed-bed and fixed-bed bioreactors applications, including cell therapy, vaccine production, recombinant proteins, and organoid formation.
Cellevat3d® nanofiber microcarriers
| Material | Nanofiber-based cellulose |
| Format | Monofibers |
| Bioreactor | Stirred tank bioreactors |
| Applications | Gene therapy, PSC’s, HEK based recombinant proteins, HEK based vaccines, organoid formation |
The commercial launch of Cellevat3d® nanofiber microcarriers is set for November 2024.
Cellevat3d® nanofiber macrocarriers
| Material | Nanofiber-based cellulose |
| Format | Cross-linked fibers |
| Bioreactor | Packed- & fixed-bed bioreactors |
| Applications | Cell therapy, MSC’s, vaccines, recombinant proteins, organoid formation |
Cellevat3d® nanofiber macrocarriers is in development. Expected launch 2026.
5 reasons to choose Cellevat3d® products
Enhanced product titers in upstream bioprocessing
Nanofiber microcarriers provide up to 60x larger surface area-to-volume ratio than current microcarriers, supporting higher cell densities and enhancing viral vector production titers.
Optimal conditions for cell growth
Nanofiber microcarriers support the formation of spheroids, providing a true 3D (three-dimensional) cell culture environment, generating high viable cell densities (VCD) in stirred tank bioreactors.
Scalable from lab- to large-scale
Nanofiber cell culture systems are easily scaled-up from cell culture flasks to large stirred tank bioreactors.
Exceptional flexibility
Nanofiber material can be functionalized and easily molded into any shape or form, allowing for integration in various production platforms for gene therapy, cell therapy and novel vaccines.
Increased productivity and improved process economy
Improved cell culture product yield, faster processes, and scale-up result in an enhanced process economy.
